What are the specific mRNA biomarkers that have been identified as a diagnostic tools for colorectal cancer?
Best insight from top research papers
Specific mRNA biomarkers identified for colorectal cancer (CRC) diagnosis include B2M, TIMP-1, and CLU . These mRNA levels were significantly elevated in plasma samples from metastatic CRC patients compared to healthy individuals, with the combined mRNA levels showing high discriminatory capacity (AUC = 0.903) . Additionally, a panel of 71 genes, including upregulated, downregulated, and genes involved in altered gene pairs, was identified as potential biomarkers for CRC diagnosis using RNA-Seq data . Furthermore, the study on small extracellular vesicles (sEVs) derived from blood sera of CRC patients and healthy controls revealed over 30k different RNAs, including lncRNAs, miRNAs, and protein-coding RNAs, indicating the potential of sEVs as a source of RNA biomarkers for CRC diagnosis .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| Specific mRNA biomarkers identified for colorectal cancer diagnosis include a panel of 71 genes, comprising the top upregulated, downregulated genes, and those involved in significantly altered gene pairs. | |
| Long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and protein-coding RNAs have been identified as potential mRNA biomarkers for colorectal cancer diagnosis using RNA sequencing of small extracellular vesicles. | |
| miR-15b, miR-21, and miR-31 have been identified as specific mRNA biomarkers with high diagnostic accuracy for colorectal cancer, showing promise for clinical use. | |
| Not addressed in the paper. | |
| B2M, TIMP-1, and CLU are specific mRNA biomarkers identified for colorectal cancer diagnosis, showing higher levels in metastatic colorectal cancer patients compared to healthy individuals. |
Related Questions
What is the diagnosis of colorectal cancer ?5 answersThe diagnosis of colorectal cancer involves various methods, including both invasive and non-invasive approaches. Invasive methods such as endoscopic evaluation and colonoscopy remain crucial for detecting and preventing the progression of adenomatous polyps to cancer. Non-invasive techniques, like molecular testing using biomarkers, play a significant role in early detection and personalized treatment strategies for colorectal cancer. Molecular markers, including piRNA-hsa-5937, have been identified as effective biomarkers for diagnosing and prognosing colorectal cancer, offering high sensitivity and specificity even in the early stages of the disease. Additionally, utilizing metagenomic analysis of extracellular vesicles and metabolites can aid in diagnosing and predicting colorectal cancer early, enhancing diagnostic accuracy and treatment outcomes.
What are the best tests for early detection of colorectal cancer?5 answersThe best tests for early detection of colorectal cancer include liquid biopsies and fecal occult blood testing (FOBT). Liquid biopsies, such as the Dxcover® Cancer Liquid Biopsy, use Fourier-transform infrared (FTIR) spectroscopy and machine learning algorithms to detect disease-specific signatures in serum samples. These tests have shown promising results in detecting multiple cancer types, including colorectal cancer, with high sensitivity and specificity. FOBT, specifically fecal immunochemical testing (FIT), is recommended as a first-line screening for colorectal cancer. FIT has been shown to have a sensitivity of 24% and FIT-DNA has a sensitivity of 42% for detecting advanced adenomas. Additionally, marker combinations in serum, including CEA, CYFRA 21-1, ferritin, osteopontin (OPN), anti-p53, and seprase, have shown comparable sensitivity to FIT in detecting colorectal cancer. These tests provide a non-invasive and cost-effective approach to early detection of colorectal cancer, improving patient prognosis and reducing mortality.
Are there any serum biomarkers that can be used to screen for colorectal cancer?5 answersSerum biomarkers that can be used to screen for colorectal cancer include adenine, bilirubin, ACar 12:0, ACar 10:1, ACar 9:0, PC 18:2e, deoxycholic acid, chenodeoxycholic acid, ACar 14:1, and palmitoylcarnitine. Additionally, the known tumor markers CEA and CYFRA 21-1, as well as novel markers such as ferritin, osteopontin (OPN), anti-p53, and seprase, have shown potential for detecting colorectal cancer in serum. Furthermore, exosomal mRNAs and lncRNAs in serum have been identified as potential biomarkers for colorectal cancer detection. These findings suggest that a combination of these biomarkers could be used for early detection of colorectal cancer and may serve as an alternative to current screening methods.
Are there any serum small biomarkers that can be used to screen for colorectal cancer?5 answersSerum small biomarkers that can be used to screen for colorectal cancer include microRNAs (miRNAs) such as miR-21, miR-29a, and miR-125b. These miRNAs have been found to have elevated levels in patients with early colorectal neoplasms compared to healthy controls, and they show potential for noninvasive screening of colorectal neoplasia. Additionally, a combination of markers including CEA, CYFRA 21-1, ferritin, osteopontin (OPN), anti-p53, and seprase has shown comparable performance to fecal immunochemical testing (FIT) for detecting colorectal cancer. Other potential serum biomarkers for early detection of colorectal cancer include GDF-15, hepsin, IL-8, keratin1-10, L1CAM, MIA, monocyte MCP-1, NSE, and OPG. These biomarkers have shown associations with colorectal cancer and could be used in combination with clinical and demographic information for screening purposes. Furthermore, serum profiling of eotaxin-1, MIP-1β, G-CSF, and VEGF-A has shown promise as potential biomarkers for early diagnosis of colorectal cancer.
What is the role of microRNA in colorectal cancer diagnosis?5 answersMicroRNAs (miRNAs) play a significant role in the diagnosis of colorectal cancer (CRC). They have been proposed as valid and reliable biomarkers for the early detection and prognosis of CRC. Studies have shown that miRNAs, such as miR-223 and miR-182, are deregulated in CRC and can be used as diagnostic and prognostic markers. Increased levels of miR-223 and miR-182 are associated with an increased risk of disease progression, and their accurate measurement can lead to earlier diagnosis of CRC. MiRNAs can be easily accessed in liquid biopsies and provide important information for the management of CRC. However, further research is needed to identify the most sensitive and specific miRNAs for different goals in CRC management. In summary, miRNAs have emerged as valuable tools for the diagnosis and prognosis of CRC, offering potential benefits for personalized health diagnostics and treatment monitoring.
What is the status of src expression in colorectal cancer ?5 answersSRC expression in colorectal cancer has been extensively studied. High SRC expression in pretreatment tumor biopsies is associated with a negative postoperative nodal status, fewer distant metastases, longer cancer-specific survival, and fewer local relapses during long-term follow-up. Additionally, SRC activation has been documented in a significant percentage of colorectal tumors, and mechanisms such as post-translational modifications and transcriptional regulation contribute to its activation. Histone deacetylase (HDAC) inhibitors have been found to repress SRC transcription in colorectal cancer cell lines, suggesting a potential therapeutic strategy for inhibiting SRC gene expression. Overall, the status of SRC expression in colorectal cancer indicates its potential as a predictive and prognostic biomarker, as well as a therapeutic target for personalized treatment approaches.